NEWS HIGHLIGHTSMedia Articles Related to Ovide (Malathion Topical)
Study Explores Providers' Perceptions Of Parental Concerns About HPV Vaccination
Source: Health News from Medical News Today [2013.05.17]
A new Boston University School of Medicine (BUSM) study has found that low-income and minority parents may be more receptive to vaccinating their daughters against Human Papillomavirus (HPV), while white, middle-class parents are more likely to defer the vaccination. The findings appear online in the May issue of the Journal of Health Care for the Poor and Underserved. Cervical cancer incidence and mortality are markedly higher for low-income and minority women due to higher rates of HPV and limited access to screening and treatment...
Excellent Crash Safety Ratings Of Passenger Cars 'May Provide A False Degree Of Confidence'
Source: Public Health News From Medical News Today [2013.05.16]
Most consumers who are shopping for a new car depend on good crash safety ratings as an indicator of how well the car will perform in a crash. But a new University at Buffalo study of crashes involving cars and sport utility vehicles (SUVs) has found those crash ratings are a lot less relevant than vehicle type...
Clues To Tooth Regeneration Provided By Alligator Stem Cell Study
Source: Dentistry News From Medical News Today [2013.05.15]
Alligators may help scientists learn how to stimulate tooth regeneration in people, according to new research led by the Keck School of Medicine of USC. For the first time, a global team of researchers led by USC pathology Professor Cheng-Ming Chuong, M.D., Ph.D., has uncovered unique cellular and molecular mechanisms behind tooth renewal in American alligators...
Genetic Test Identifies Two Types Of Leukemia; Discovery Provides Insights Into New Treatment Approach
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2013.05.14]
Research method used by scientists with the Knight Cancer Institute at Oregon Health & Science University shows promise in accelerating advances in personalized cancer medicine Patients with two forms of leukemia, who currently have no viable treatment options, may benefit from existing drugs developed for different types of cancer, according to a study conducted by research...
Abortion Provider Guilty of Murder, Other Charges
Source: Medscape Today Headlines [2013.05.13]
A Philadelphia jury has delivered its verdict on the murder of infants and other charges in the case of an abortion service provider run amok.
Medscape Medical News
Published Studies Related to Ovide (Malathion Topical)
Oral ivermectin for head lice: a comparison with 0.5 % topical malathion lotion. [2010.12]
BACKGROUND: Reports of treatment failure of head lice have become increasingly common. Oral ivermectin has been proposed as a potential alternative for the treatment of head lice infestation. The aim of this study was to compare the efficacy of oral ivermectin with topical malathion lotion in the treatment of head lice... CONCLUSIONS: Oral ivermectin is a promising effective approach for the treatment of head lice and could be an ideal substitute for conventional pediculicides. (c) The Author * Journal compilation (c) Blackwell Verlag GmbH, Berlin.
Oral ivermectin versus malathion lotion for difficult-to-treat head lice. [2010.03.11]
BACKGROUND: Head-lice infestation is prevalent worldwide, especially in children 3 to 11 years old. Topical insecticides (i.e., pyrethroids and malathion) used as a lotion, applied twice at an interval of 7 to 11 days, are typically used for treatment. Resistance of lice to insecticides, particularly pyrethroids, results in treatment failure. The efficacy of alternative agents is controversial... CONCLUSIONS: For difficult-to-treat head-lice infestation, oral ivermectin, given twice at a 7-day interval, had superior efficacy as compared with topical 0.5% malathion lotion, a finding that suggests that it could be an alternative treatment. (ClinicalTrials.gov number, NCT00819520.) 2010 Massachusetts Medical Society
Randomised, controlled, assessor blind trial comparing 4% dimeticone lotion with 0.5% malathion liquid for head louse infestation. [2007.11.07]
BACKGROUND: Malathion 0.5% has been the most prescribed pediculicide in the United Kingdom for around 10 years, and is widely used in Europe and North America...
Efficacy of a reduced application time of Ovide lotion (0.5% malathion) compared to Nix creme rinse (1% permethrin) for the treatment of head lice. [2004.11]
Our objective was to conduct a randomized, investigator-blinded evaluation of the pediculicidal and ovicidal activity of a reduced application time (20 minutes) of Ovide (0.5% malathion) compared to Nix (1% permethrin) in a south Florida population infested with Pediculus humanus capitis...
Oral ivermectin for head lice: a comparison with 0.5 % topical malathion lotion. [2010.08.13]
Summary Background: Reports of treatment failure of head lice have become increasingly common...
Clinical Trials Related to Ovide (Malathion Topical)
Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice [Completed]
Current treatments for head lice include over-the-counter products such as permethrin and
prescription products such as OVIDE (malathion 0. 5%) lotion. In a previous phase II study, a
novel, easy-to-use malathion 0. 5% formulation was found to be a safe treatment for head lice.
The current study will compare the efficacy and safety of this novel formulation of
malathion with OVIDE and with an over-the-counter permethrin product.
Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice [Recruiting]
In a previous phase II study, the safety and efficacy of a novel formulation of malathion
0. 5% was evaluated in patients 2 years of age and older. Based on the results of that study,
this formulation is currently in a phase III study for that population.
The current study will use blood markers and clinical evaluations to determine the safety
and tolerability of this formulation when used in children 6-24 months of age.
Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice [Recruiting]
In this study, Malathion Gel 0. 5% will be compared to Nix (permethrin 1%) as a treatment for
head lice in patients 2 years of age and older. Malathion Gel 0. 5% is a new formulation of
an established head lice treatment. The new formulation has been evaluated in 2 previous
studies of patients 2 years of age and older.
Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice [Recruiting]
In this study, Malathion Gel 0. 5% will be compared to Nix (permethrin 1%) as a treatment for
head lice in patients 2 years of age and older. Malathion Gel 0. 5% is a new formulation of
an established head lice treatment. The new formulation has been evaluated in 2 previous
studies of patients 2 years of age and older.
Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice [Terminated]
In a previous phase II study, the safety and efficacy of a novel formulation of malathion
0. 5% was evaluated in patients 2 years of age and older. Based on the results of that study,
this formulation is currently in a phase III study for that population.
The current study will use blood markers and clinical evaluations to determine the safety and
tolerability of this formulation when used in children 6-24 months of age.
Reports of Suspected Ovide (Malathion Topical) Side Effects
Application Site Burn (3),
Burns Second Degree (3),
Fall (2),
Loss of Consciousness (2),
Skin Infection (2),
Accidental Exposure (2),
Chemical Injury (2),
Muscle Atrophy (1),
Peroneal Nerve Palsy (1),
Oedema Peripheral (1), more >>
|
